XMT-1536 (Upifitamab Rilsodotin) for Platinum-Sensitive Ovarian Cancer
This trial tests the safety of a new antibody-drug conjugate (XMT-1536) for ovarian cancer. The trial has two parts: a dose escalation portion to find a safe dose, and an expansion portion to study how well the drug works.
- Platinum-Sensitive Ovarian Cancer
3 Primary · 11 Secondary · Reporting Duration: Every 8 weeks for the first 12 months, then every 12 weeks on treatment
2 Treatment Groups
Dose Expansion - Module A (UPGRADE-A)
1 of 2
Dose Escalation - Module A (UPGRADE-A)
1 of 2
48 Total Participants · 2 Treatment Groups
Primary Treatment: XMT-1536 (Upifitamab Rilsodotin) · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · Female Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Where are the different places this trial is running?
"Presently, this clinical trial is looking for participants from 12 different sites. Some of these locations include Tucson, Columbus and Burlington. To reduce travel difficulties, it is best to select the site that is closest to your location." - Anonymous Online Contributor
Is there previous research to support the use of Carboplatin?
"Carboplatin was first trialed in 2002 at the H Central de Asturias medical facility. In the ensuing years, there have been 833 completed clinical trials worldwide. As of right now, 727 different carboplatin trials are actively recruiting patients; a large number of these studies are based in Tucson, Arizona." - Anonymous Online Contributor
How is Carboplatin most commonly employed in medical treatment?
"Carboplatin is most often used to treat non-hodgkin lymphoma. This chemotherapy can also be effective in treating advanced sarcoma, hodgkin disease, and certain cases of newly diagnosed cancer." - Anonymous Online Contributor
Are patients currently being enrolled in this trial?
"That is correct. By visiting clinicaltrials.gov, one can see that this trial was posted on 6/11/2021 and is still actively looking for participants. The study will have 48 patients total across 12 locations." - Anonymous Online Contributor
How many participants will this study have in total?
"Yes, as of 8/30/2022 this study is still recruiting participants. The trial was initially posted on 6/11/2021 and requires 48 patients from 12 different sites." - Anonymous Online Contributor